FDA Approves TAUKLARIFY (florquinitau F 18 injection) for Detecting Tau Pathology in Alzheimer's Disease

The U.S. Food and Drug Administration (FDA) has approved TAUKLARIFY (florquinitau F 18 injection), a tau PET imaging agent, for identifying tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer's disease. This diagnostic tool is expected to enhance the understanding of Alzheimer's disease progression, particularly in early stages.